Cases

*173ROTH, Circuit Judge, dissenting. I believe “storm warnings” alerting a reasonable investor of possible culpable activity on the part of Merck were evident more than two years prior to the filing of appellants’ complaint. In particular, I believe that the FDA’s September 17, 2001, warning letter, in and of itself, provided sufficient “storm wa

450 F.Supp.2d 582 (2006) Julius WEBB, et al. Plaintiffs, v. MERCK & CO., INC., Defendant. No. Civ.A. 99-413. United States District Court, E.D. Pennsylvania. September 8, 2006. *583 *584 *585 Adrian J. Moody, Joseph C. Kohn, Martin J. D'Urso, Law Office

341 F.Supp.2d 1054 (2004) Anita IVORY, Plaintiff, v. MERCK & CO., INC., Defendant. No. 04 C 6762. United States District Court, N.D. Illinois, Eastern Division. October 26, 2004. *1055 Daniel A. Edelman, Edelman, Combs, Latturner & Goodwin, LLC, Chicago, IL, for Plaintiff. Eugene Edward Murphy, Jr., Horwood, Marcus

*637Justice Breyer delivered the opinion of the Court. This ease concerns the timeliness of a complaint filed in a private securities fraud action. The complaint was timely if filed no more than two years after the plaintiffs “discover[ed] the facts constituting the violation.” 28 U. S. C. § 1658(b)(1). Construing this limitations statute for the first t

(Slip Opinion) OCTOBER TERM, 2009 1 Syllabus NOTE: Where it is feasible, a syllabus (headnote) will be released, as is being done in connection with this case, at the time the opinion is issued. The syllabus constitutes no part of the opinion of the Court but has been prepared by the Reporter of Decisions for the convenience of the reader. See United States v. Detroit

(Slip Opinion) OCTOBER TERM, 2009 1 Syllabus NOTE: Where it is feasible, a syllabus (headnote) will be released, as is being done in connection with this case, at the time the opinion is issued. The syllabus constitutes no part of the opinion of the Court but has been prepared by the Reporter of Decisions for the convenience of the reader. See United States v. Detroit

Opinions of the United 2007 Decisions States Court of Appeals for the Third Circuit 7-18-2007 In Re: Merck & Co Precedential or Non-Preceden

79 F.Supp.2d 552 (2000) MERCK & CO., INC., Plaintiff, v. MYLAN PHARMACEUTICALS, INC., Defendant. No. CIV. A. 97-CV-4241. United States District Court, E.D. Pennsylvania. January 12, 2000. *553 Mary B. Graham, Matthew B. Lehr, Lisa B. Baeurle, Julia Heaney, Richard H. Cross, Jr., Richard L. Sutton, MaryEllen Noreika, Rodney Ca

ORDER AND REASONS FALLON, District Judge. Pending before the Court is David Ans-tice and Merck & Co., Inc.’s (“Merck”) Motion to Quash Subpoena (Rec.Doc. 5758). For the following reasons, the motion is DENIED. I. BACKGROUND Mr. Anstiee is currently Merck & Co., Inc.’s (“Merck”) President of Human Health for Canada, Latin America, Japan, A

19 F.Supp.2d 334 (1998) MERCK & CO., INC., Plaintiff, v. MYLAN PHARMACEUTICALS, INC., Defendant. Civil Action No. 97-CV-4241. United States District Court, E.D. Pennsylvania. August 24, 1998. *335 *336 David P. Bruton, Drinker, Biddle & Reath, Philadelphia, PA, James H. Wallace, Jr., G

Memorandum Opinion and Order Honorable Edmond E. Chang, United States District Judge Antonio Torres has worked at Merck Sharp & Dohme as a customer representative since 2007. R. 44, First Am. Compl. at 2.1 Torres alleges that Merck took away career opportunities after finding out that he has rheumatoid arthritis and then took further retaliatory action once Torres filed a

941 F.Supp. 1443 (1996) MERCK & CO. INC., Merck Frosst Canada, Inc. and Johnson & Johnson * Merck Consumer Pharmaceuticals Co., Plaintiffs, v. Gary A. LYON and Glaxo Wellcome, Inc., Defendants. No. 1:96CV245. United States District Court, M.D. North Carolina, Durham Division. September 11, 1996. *1444

MEMORIALIZING OPINION Re: Final Approval of Biotin and Niacin Defendants Settlements THOMAS F. HOGAN, Chief Judge. Pending before the Court is class plaintiffs’ Motion pursuant to Fed.R.Civ.P. 23(e) and 54 for Final Approval of Settlement Between Class Plaintiffs and Defendants Sumitomo Chemical Co., Ltd., Sum-itomo Chemical America, Inc., Tanabe

ORDER NORGLE, District Judge. Before the court is Magistrate Judge Rebecca R. Pallmeyer's 83-page Report and Recommendation (the “Report”), dated November 13, 1992, which recommends: (1) granting Merck’s motion for summary judgment asserting that all claims of Zumbro’s patent are invalid on account of the inventors’ failure to comply with the best mode requirement of 35 U.S.C. § 112; (2) or alternative

NEWMAN, Circuit Judge, dissenting. This appeal is from a decision of the Patent Trial and Appeal Board (“PTAB”), on Inter Partes Review in accordance with the America Invents Act. The PTAB held the claims of the patent in suit invalid. My concern is with the court’s implementation of this new statute, lest its legislative purpose be unfulfilled. The America Invents Act (“AIA”) is the fruit o

W. FLETCHER, Circuit Judge: The Class Action Fairness Act (“CAFA”), Pub.L. No. 109-2, 119 Stat. 4 (2005), authorizes the removal to federal court of “mass actions.” 28 U.S.C. § 1332(d)(ll)(A), (B). “Mass actions” are civil actions in which “monetary relief claims of 100 or more persons are proposed to be tried jointly on the ground that the plaintiffs’ claims involve common ques

AMBRO, Circuit Judge. Merck & Co., Inc. planned an initial public offering of its wholly owned subsidiary — Medco Health Solutions, Inc. Before the IPO was to occur, however, information about Medco’s aggressive revenue-recognition policy came to light. Some details about the policy were disclosed in Merck’s registration statements filed with the Securities and Exchange Comm

493 F.3d 393 (2007) In re MERCK & CO., INC. SECURITIES, DERIVATIVE & ERISA LITIGATION. Consolidated Derivative Action. Hawaii Laborers Pension Plan and Halpert Enterprises, Inc., Appellants. No. 06-2911. United States Court of Appeals, Third Circuit. Argued April 12, 2007. Filed July 18, 2007. *394

MEMORANDUM OPINION AND ORDER DANNY C. REEVES, District Judge. This matter is pending for consideration of Defendant Jack Conway’s renewed motion to dismiss. [Record No. 36] Conway, the Kentucky Attorney General (“AG”), seeks dismissal of Plaintiff Merck Sharp & Dohme Corporation’s (“Merck”) complaint on abstention grounds. For the reasons explained below, the AG’s motion will be denied. <

Opinion after Bench Trial RICHARD J. SULLIVAN, District Judge. Plaintiff Merck & Cie (“Merck”), formerly known as Merck Eprova AG, a producer of pharmaceutical and dietary ingredients, brings this action against Defendants Gnosis S.p.A. and Gnosis Bioresearch S.A. (collectively, “Gnosis”), manufacturers and sellers of raw ingredients to nutritional companies, for misleading advertising in connection with